Critical review of oral drug treatments for diabetic neuropathic pain - Clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies

Diabetes/Metabolism Research and Reviews

Volumn 21, Issue 3, 2005, Pages 231-240

  Adriaensen, Hugo ^a   Plaghki, Léon ^b   Mathieu, Chantal ^c   Joffroy, Alfred ^d   Vissers, Kris ^e  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ERASME HOSPITAL   (Belgium)

^e DEPARTMENT OF CARDIOLOGY   (Belgium)

Author keywords

Diabetes mellitus; Diabetic complications; Diabetic neuropathy; Neuropathic pain; Review

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIDIABETIC AGENT; BENZATROPINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DEXTROMETHORPHAN; FLUOXETINE; FLUPHENAZINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LEVACECARNINE; MEXILETINE; NORTRIPTYLINE; OXYCODONE; PAROXETINE; PLACEBO; TRAMADOL; VALPROIC ACID;

BODY WEIGHT DISORDER; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIZZINESS; DOSE CALCULATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; INSOMNIA; MAXIMUM PERMISSIBLE DOSE; MEMORY DISORDER; NAUSEA; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STANDARDIZATION; SWEATING; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; CONTROLLED CLINICAL TRIALS; DIABETIC NEUROPATHIES; HUMANS;

EID: 19144367500     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.552     Document Type: Review

References (54)

1. Backonja M. Managing painful diabetic neuropathy. Hosp Pract (Off Ed) 1999; 34: 79-88.
2. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999; 353: 1959-1964.
3. Herman WA, Greene DA. Microvascular complications of diabetes. In Management of Diabetes Mellitus, Harro-Joshu D (ed). CV Mosby: St. Louis, Mo, 1996; 234-280.
4. McLeod JG. Investigation of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1995; 58: 274-283.
5. Pfeifer MA, Ross DR, Schrage JP, et al. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993; 16: 1103-1115.
6. Thomas PK, Thomlinson DR. Diabetic and hypoglycaemic neuropathy. In Peripheral Neuropathy, Dyck PJ, Thomas PK, Griffin JW, Low PA, Podulso JF (eds). WB Saunders: Philadelphia, PA, 1993; 1219-1250.
7. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; 1: 168-263.
8. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824.
9. Walters DR, Gatling W, Mullee MA, Hill RD. The prevalence of diabetic distal sensory neuropathy in an English community. Diabet Med 1992; 9: 349-353.
10. Chan AW, MacFarlane IA, Bowsher D, et al. Chronic pain in patients with diabetes mellitus: comparison with a non-diabetic population. The Pain Clinic 1990; 3: 147-159.
11. Ziegler D, Gries FA, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy. J Diabetes Complications 1992; 6: 49-57.
12. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977-986.
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
14. Greene DA, Stevens MJ, Feldman EL, Diabetic neuropathy: scope of the syndrome. Am J Med 1999; 107: 2S-8S.
15. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000; 20: 449-458.
16. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389-400.
17. McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995; 311: 1047-1052.
18. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-1256.
19. Sindrup SH, Gram LF, Skjold T, et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol 1990; 30: 683-691.
20. Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135-144.
21. Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45: 3-9.
22. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547-552.
23. Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999; 83: 85-90.
24. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-1846.
25. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy. Neurology 2003; 60: 927-934.
26. Watson CPN, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71-78.
27. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. Pain 1999; 83: 105-107.
28. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy. A randomized, controlled study. Neurology 2001; 57: 505-509.
29. Kochar DK, Jain N, Agarwal RP, et al. Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study. Acta Neurol Scand 2002; 106: 248-252.
30. Backonja M, Beydoun A, Edwards KR, et al. for the Gabapentin Diabetic Neuropathy Study Group. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-1836.
31. Gorson KG, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999; 66: 251-252.
32. Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997; 48: 1212-1218.
33. Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; 1: 9-11.
34. Oskarsson P, Ljunggren J-G, Lins P-E. and the Mexilitine Study Group. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care 1997; 20: 1594-1597.
35. Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexilitine in the treatment of diabetic neuropathy. Diabetes Care 1992; 15: 1550-1555.
36. De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D 2002; 3: 223-231.
37. Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931-1937.
38. Gomez-Perez FJ, Choza R, Rios JM, et al. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996; 27: 525-529.
39. Gracely RH, McGrath P, Dubner R. Ratio scales of sensory and affective verbal pain descriptors. Pain 1978; 5: 5-18.
40. Calissi PT, Jaber LA. Peripheral diabetic neuropathy: current concepts in treatment. Ann Pharmacother 1995; 29: 769-777.
41. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589-596.
42. Sindrup SH, Ejlertsen B, Froland A, et al. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989; 37: 151-153.
43. Bonezzi G, Demartini L. Treatment options in postherpetic neuralgia. Acta Neurol Scand Suppl 1999; 173: 25-35.
44. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-285.
45. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969; 5: 215-218.
46. Wilton TD. Tegretol in the treatment of diabetic neuropathy. S Afr Med J 1974; 48: 869-872.
47. Chadda VS, Mathur MS. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India 1978; 26: 403-406.
48. Saudek CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 1977; 22: 196-199.
49. Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res 1993; 612: 190-199.
50. Teoh H, Fowler U, Bowery NG. Effect of lamotrigine on the electrically-evoked release of endogenous amino acids from slices of dorsal horn of the rat spinal cord. Neuropharmacology 1995; 34: 1273-1278.
51. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000; 101: 359-371.
52. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug gabapentin (Neurontin) binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271(10): 5768-5776.
53. Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 1998; 37: 83-91.
54. Backonja MM. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 2000; 16: S67-S72.